Reactome | CYSLTR1 binds CYSLTR1 antagonists

CYSLTR1 binds CYSLTR1 antagonists

Stable Identifier

R-HSA-9684627

Type

Reaction [binding]

Species

Homo sapiens

Compartment

extracellular region, plasma membrane

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

Signal Transduction (Homo sapiens)

- Signaling by GPCR (Homo sapiens)
  - GPCR ligand binding (Homo sapiens)
    - Class A/1 (Rhodopsin-like receptors) (Homo sapiens)
      - Eicosanoid ligand-binding receptors (Homo sapiens)
        
        Leukotriene receptors (Homo sapiens)
        
        CYSLTR1 binds CYSLTR1 antagonists (Homo sapiens)

General

SBML | | PDF

SVG | | PPTX | SBGN

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Cysteinyl leukotriene receptor 1 (CYSLTR1) is a GPCR through which leukotriene D4 mediates bronchoconstriction. CYSLTR1 antagonists work by antagonising the effects of proinflammatory leukotrienes (such as LTC4, LTD4 and LTE4), resulting in decreased inflammation and decreased hyperresponsiveness of airways to immune challenges (Capra et al. 1998, Snyder & Fleisch 1989, Wendell et al. 2020). The CYSLTR1 antagonists listed here comprise approved (montelukast, pranlukast and zafirlukast) and investigational drugs used in asthma therapy.

Literature References

PubMed ID	Title	Journal	Year
2543269	Leukotriene receptor antagonists as potential therapeutic agents Snyder, DW, Fleisch, JH	Annu. Rev. Pharmacol. Toxicol.	1989
9504401	Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro Bolla, M, Mezzetti, M, Nicosia, S, Belloni, PA, Folco, GC, Capra, V, Rovati, GE	Br. J. Pharmacol.	1998